Rojas-Prats, E.; Martinez-Gonzalez, L.; Gonzalo-Consuegra, C.; Liachko, N. F.; Perez, C.; Ramírez, D.; Kraemer, B. C.; Martin-Requero, Á.; Perez, D. I.; Gil, C.; de Lago, E.; Martinez, A.  [2020]. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem 2020, doi: 10.1016/j.ejmech.2020.112968

Canal-Martín, A.; Pérez-Fernández, R.  [2020]. Protein-directed dynamic combinatorial chemistry: An efficient strategy in drug design. ACS Omega 2020, 5, 26307-26315

Vaca, G.; Martínez-González, L.; Fernández, A.; Rojas-Prats, E.; Porras, G.; Cuevas, E. P.; Gil, C.; Martinez, A.; Martin-Requero, A.  [2020]. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and Amyotrophic Lateral Sclerosis (ALS). J Neurochem 2020, doi: 10.1111/jnc.15118

Palomo, V.; Nozal, V.; Rojas-Prats, E.; Gil, C.; Martinez, A.  [2020]. Protein kinase inhibitors for Amyotrophic Lateral Sclerosis therapy. Br J Pharmacol 2020, doi: 10.1111/bph.15221

Martinez-Gonzalez, L.; Rodríguez-Cueto, C.; Cabezudo, D.; Bartolome, F.; Andrés-Benito, P.; Ferrer, I.; Gil, C.; Martin-Requero, A.; Fernández-Ruiz, J.; Martinez, A.; de Lago, E.  [2020]. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Sci. Rep. 2020, 10, 4449.

Castro-Sánchez, S.; Zaldivar-Diez, J.; Luengo, E.; López, M. G.; Gil, C.; Martínez, A.; Lastres-Becker, I.  [2020]. Cognitive enhancement, tau phosphorylation reduction and neuronal protection by the treatment of a LRRK2 inhibitor in a tauopathy mouse model. Neurobiol. Aging 2020, 96, 148-154.

Zaldivar-Diez, J.; Li, L.; Garcia, A. M.; Zhao, W.-N.; Medina-Menendez, C.; Haggarty, S. J.; Gil, C.; Morales, A. V.; Martínez, A.  [2020]. Benzothiazole-based LRRK2 inhibitors as Wnt enhancers and promoters of oligodendrocytic fate. J. Med. Chem. 2020, 63, 2638-2655.

Gil, C.; Ginex, T.; Maestro, I.; Nozal, V.; Barrado-Gil, L.; Cuesta-Geijo, M. A.; Urquiza, J.; Ramirez, D.; Alonso, C.; Campillo, N. E.; Martinez, A.  [2020]. COVID-19: Drug targets and potential treatments. J Med Chem 2020, 63, 12359-12386.

Maestro, I.; Boya, P.; Martinez, A.  [2020]. Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. Expert Opin Ther Targets 2020, 24 (3), 231-243.

Peřinová, R.; Maafi, N.; Korábečný, J.; Kohelová, E.; De Simone, A.; Al Mamun, A.; Hulcová, D.; Marková, J.; Kučera, T.; Jun, D.; Šafratová, M.; Maříková, J.; Andrisano, V.; Jenčo, J.; Kuneš, J.; Martinez, A.; Nováková, L.; Cahlíková, L.  [2020]. Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer's disease. Bioorg Chem 2020, 100, 103928.

Di Martino, R. M. C.; Pruccoli, L.; Bisi, A.; Gobbi, S.; Rampa, A.; Martinez, A.; Pérez, C.; Martinez-Gonzalez, L.; Paglione, M.; Di Schiavi, E.; Seghetti, F.; Tarozzi, A.; Belluti, F.  [2020]. Novel curcumin-diethyl fumarate hybrid as a dualistic GSK-3β inhibitor/Nrf2 inducer for the treatment of Parkinson's disease. ACS Chem Neurosci 2020, 11 (17), 2728-2740.

Martinez-Gonzalez, L.; Rodríguez-Cueto, C.; Cabezudo, D.; Bartolome, F.; Andrés-Benito, P.; Ferrer, I.; Gil, C.; Martin-Requero, A.; Fernández-Ruiz, J.; Martinez, A.; de Lago, E.  [2020]. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Sci. Rep. 2020, 10, 4449

Sebastián-Pérez, V.; García-Rubia, A.; Seif el-Din, S. H.; Sabra, A.-N. A.; El-Lakkany, N. M.; William, S.; Blundell, T. L.; Maes, L.; Martinez, A.; Campillo, N. E.; Botros, S. S.; Gil, C.  [2020]. Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. J. Enz. Inh. Med. Chem. 2020, 35, 511-523.

Martínez de Iturrate, P.; Sebastián-Pérez, V.; Nácher-Vázquez, M.; Tremper, C. S.; Smirlis, D.; Martin, J.; Martínez, A.; Campillo, N. E.; Rivas, L.; Gil, C.  [2020]. Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. J. Enz. Inh. Med. Chem. 2020,35, 199-210.

Canal-Martín, A.; Sastre, J.; Sánchez-Barrena, M. J.; Canales, A.; Baldominos, S.; Pascual, N.; Martínez-González, L.; Molero, D.; Fernández-Valle, M. E.; Sáez, E.; Blanco-Gabella, P.; Gómez-Rubio, E.; Martín-Santamaría, S.; Sáiz, A.; Mansilla, A.; Cañada, F. J.; Jiménez-Barbero, J.; Martínez, A.; Pérez-Fernández, R.  [2019]. Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. Nat Commun 2019, 10, 2798.

Botros, S. S.; Williams, S.; Sabra, A-N. A.; El-Lakkany, N. M.; Seif el-Din, S. H.; Sterk, G. J.; Salado, I. G.; Augustyns, K.; García-Rubia, A.; Sebastian-Perez, V.; Maes, L.; Munday, J. C.; Leurs, R.; Gil, C.; De Koning, H. P  [2019]. Antischistosomal screening of a PDE-focused library identifies imidazoles with in vitro and in vivo activity. Int. J. Parasitol.: Drugs Drug Resist. 2019, 9, 35-43.

de Araújo, J. S.; Garcia-Rubia, A.; Sebastian-Perez, V.; Kalejaiye, T. D.; Bernardino da Silva, P.; Fonseca-Berzal, C. R.; Maes, L.; De Koning, H.; Soeiro, M. N. C.; Gil, C.  [2019]. Imidazole derivatives as promising agents for the treatment of Chagas disease. Antimicrob. Agents Chemother. 2019, 63, e02156-18.

Sebastián-Pérez, V.; Martinez, M. J.; Gil, C.; Campillo, N. E.; Martinez, A.; Ponzoni, I.  [2019]. Inference of QSAR Models for identifying LRRK2 inhibitors for the treatment of Parkinson’s Disease. J. Integr. Bioinform. 2019, 20180063.

Martinez, A.; Gil, C.  [2019]. “Protein kinase inhibitors for the treatment of Multiple Sclerosis” en Emerging Drugs and Targets for Multiple Sclerosis. Ed. A. Martínez, Royal Society of Chemistry. 2019, 170-196.

Sebastian-Pérez, V.; Schroeder, S.; Munday, J. C.; van der Meer, T.; Zaldívar-Díez, J.; Siderius, M.; de Koning, H. P.; Brown, D.; Martinez, A.; Campillo, N. E.; Leurs, R.; Gil, C.  [2019]. Discovery of novel Schistosoma mansoni SmPDE4A inhibitors as potential agents against schistosomiasis. Fut. Med. Chem. 2019, 11, 1703-1720.